Ajanta Pharma Buyback 2024 vs Anand Rathi Buyback 2024

Comparison between Ajanta Pharma Buyback 2024 and Anand Rathi Buyback 2024.

Buyback Details

Ajanta Pharma Buyback 2024 is a Tender Offer buyback proposed to list at BSE, NSE while Anand Rathi Buyback 2024 is a Tender Offer proposed to list at BSE, NSE.

 Ajanta Pharma Ltd.Anand Rathi Wealth Ltd.
LogoAjanta Pharma Buyback 2024 LogoAnand Rathi Buyback 2024 Logo
Type of BuybackTender OfferTender Offer
Listing AtBSE, NSEBSE, NSE
Face Value₹2 per share₹5 per share
Buyback Price₹2770 per share₹4450 per share
Issue Size10,28,881 shares3,70,000 shares
Issue Size (Amount)₹285.00 Crores₹164.65 Crores
Buyback Ratio
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders1 Equity Shares out of every 8 Fully paid-up Equity Shares held on the Record Date.154,333.00
General Category for all other Eligible Shareholders1 Equity Shares out of every 128 Fully paid-up Equity Shares held on the Record Date.874,548.00
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders37 Equity Shares out of every 483 Fully paid-up Equity Shares held on the Record Date.55,500.00
General Category for all other Eligible Shareholders3 Equity Shares out of every 392 Fully paid-up Equity Shares held on the Record Date.314,500.00
RegistrarMUFG Intime India Pvt.Ltd.MUFG Intime India Pvt.Ltd.
Lead ManagersVivro Financial Services Pvt.Ltd.Mark Corporate Advisors Pvt.Ltd.
Necessity of the buyback

Buyback is being undertaken, inter-alia, for the following reasons:

  1. The Buyback will help the Company to return surplus cash to its shareholders holding Equity Shares broadly in proportion to their shareholding, thereby, enhancing the overall return to shareholders;
  2. The Buyback, which is being implemented through the tender offer route as prescribed under the SEBI Buyback Regulations, would involve the allocation of the number of Equity Shares as per their entitlement or 15% of the number of Equity Shares to be bought back whichever is higher, reserved for the small shareholders. The Company believes that this reservation for small shareholders would benefit a large number of public shareholders, who would be classified as "small shareholders" as per Regulation 2(i)(n) of the SEBI Buyback Regulations;
  3. The Buyback may help in improving its earnings per share and return on equity, by reduction in the equity base, thereby leading to a long-term increase in shareholders' value; and
  4. The Buyback gives an option to the shareholders holding Equity Shares of the Company, who can choose to participate and get cash in lieu of Equity Shares to be accepted under the Buyback offer or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post the Buyback offer, without additional investment.

Buyback is being undertaken, inter-alia, for the following reasons:

  1. The Buyback will help the Company to return surplus cash to its shareholders holding Equity Shares broadly in proportion to their shareholding, thereby, enhancing the overall return to shareholders;
  2. The Buyback will help the company to optimize capital structure;
  3. The Buyback, which is being implemented through the tender offer route as prescribed under the SEBI Buyback Regulations, would involve the allocation of the number of Equity Shares as per their entitlement or 15% of the number of Equity Shares to be bought back whichever is higher, reserved for the small shareholders. The Company believes that this reservation for small shareholders would benefit a large number of public shareholders, who would be classified as "small shareholders" as per Regulation 2(i)(n) of the SEBI Buyback Regulations;
  4. The Buyback may help in improving its earnings per share and return on equity, by reduction in the equity base, thereby leading to a long-term increase in shareholders' value; and
  5. The Buyback gives an option to the shareholders holding Equity Shares of the Company, who can choose to participate and get cash in lieu of Equity Shares to be accepted under the Buyback offer or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post the Buyback offer, without additional investment.

Buyback Timetable

Ajanta Pharma Buyback 2024 and Anand Rathi Buyback 2024 buyback timetable. The investors should have the company's shares in their demat accounts as of the record date. Ajanta Pharma Buyback 2024 Buyback record date is May 30, 2024. Anand Rathi Buyback 2024 Buyback record date is Jun 03, 2024.

 Ajanta Pharma Ltd.Anand Rathi Wealth Ltd.
Record DateMay 30, 2024Jun 03, 2024
Offer Open DateJun 05, 2024Jun 07, 2024
Offer Closure DateJun 11, 2024Jun 13, 2024
Last date for receipt of tender formsJun 11, 2024Jun 13, 2024
Finalisation of buybackJun 18, 2024Jun 19, 2024
Last Date for settlment of bidsJun 19, 2024Jun 21, 2024
Last Date for extinguishment of sharesJun 28, 2024Jul 02, 2024

Financial Details and Other Relevent Information

Comparison of Ajanta Pharma Buyback 2024 and Anand Rathi Buyback 2024 financial data. The table below also includes a list of all relevant information like Stock Market Data, Compay Information, Lead Manager and Registrar.

 Ajanta Pharma Ltd.Anand Rathi Wealth Ltd.
Financial

Ajanta Pharma Limited Financial Information (Restated Consolidated)

Ajanta Pharma Limited's revenue increased by 11.77% and profit after tax (PAT) rose by 38.81% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended31 Mar 202431 Mar 202331 Mar 2022
Assets4,638.394,679.02
Revenue4,293.313,841.283,456.67
Profit After Tax816.17587.98712.68
Amount in ₹ Crore

Anand Rathi Wealth Limited Financial Information (Restated Consolidated)

Anand Rathi Wealth Limited's revenue increased by 34.68% and profit after tax (PAT) rose by 33.94% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended31 Mar 202431 Mar 202331 Mar 202231 Mar 2021
Assets624.12480.16339.75
Revenue751.97558.33425.63279.25
Profit After Tax225.82168.60126.8044.62
Reserves and Surplus486.12360.97267.29
Amount in ₹ Crore
Stock price at BSE

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
May-2024 2531.95 2210.05 2305.05
Apr-2024 2309.00 2049.75 2155.84
Mar-2024 2307.05 2003.55 2125.08

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
May-2024 4075.20 3850.35 3965.90
Apr-2024 4246.00 3430.00 3892.26
Mar-2024 4199.80 3437.05 3752.24
Stock price at NSE

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
May-2024 2540.00 2210.00 2308.93
Apr-2024 2311.95 2051.60 2156.03
Mar-2024 2317.65 1998.35 2127.73

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
May-2024 4088.00 3850.00 3966.43
Apr-2024 4248.00 3424.00 3890.40
Mar-2024 4050.00 3440.00 3753.70

Compare with others

Compare:

Ajanta Pharma Buyback 2024 and Anand Rathi Buyback 2024